These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16314820)

  • 41. Heterologous prime-boost vaccination strategies for HIV-1: augmenting cellular immune responses.
    Newman MJ
    Curr Opin Investig Drugs; 2002 Mar; 3(3):374-8. PubMed ID: 12054082
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Obstacles and progress toward development of a preventive HIV vaccine.
    Heyward WL; MacQueen KM; Jaffe HW
    J Int Assoc Physicians AIDS Care; 1997 Aug; 3(8):28-34. PubMed ID: 11364630
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of a DNA-MVA/HIVA vaccine for Kenya.
    Hanke T; McMichael AJ; Mwau M; Wee EG; Ceberej I; Patel S; Sutton J; Tomlinson M; Samuel RV
    Vaccine; 2002 May; 20(15):1995-8. PubMed ID: 11983261
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HIV vaccine strategies.
    Nabel GJ
    Vaccine; 2002 May; 20(15):1945-7. PubMed ID: 11983251
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preventive HIV-1 vaccines: where are we going?
    Kent SJ
    Int J STD AIDS; 1998 Dec; 9(12):715-9. PubMed ID: 9874116
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current progress in the development of HIV vaccines.
    Spearman P
    Curr Pharm Des; 2006; 12(9):1147-67. PubMed ID: 16515492
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design and tests of an HIV vaccine.
    McMichael A; Mwau M; Hanke T
    Br Med Bull; 2002; 62():87-98. PubMed ID: 12176852
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1.
    Ranasinghe C; Medveczky JC; Woltring D; Gao K; Thomson S; Coupar BE; Boyle DB; Ramsay AJ; Ramshaw IA
    Vaccine; 2006 Jul; 24(31-32):5881-95. PubMed ID: 16759767
    [TBL] [Abstract][Full Text] [Related]  

  • 49. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
    J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost.
    Virnik K; Nesti E; Dail C; Scanlan A; Medvedev A; Vassell R; McGuire AT; Stamatatos L; Berkower I
    Vaccine; 2018 Aug; 36(34):5166-5172. PubMed ID: 30037665
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The quest for an HIV vaccine].
    Girard MP
    Bull Acad Natl Med; 2005 May; 189(5):831-44; discussion 844. PubMed ID: 16433455
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.
    Casimiro DR; Chen L; Fu TM; Evans RK; Caulfield MJ; Davies ME; Tang A; Chen M; Huang L; Harris V; Freed DC; Wilson KA; Dubey S; Zhu DM; Nawrocki D; Mach H; Troutman R; Isopi L; Williams D; Hurni W; Xu Z; Smith JG; Wang S; Liu X; Guan L; Long R; Trigona W; Heidecker GJ; Perry HC; Persaud N; Toner TJ; Su Q; Liang X; Youil R; Chastain M; Bett AJ; Volkin DB; Emini EA; Shiver JW
    J Virol; 2003 Jun; 77(11):6305-13. PubMed ID: 12743287
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T cell immunity in HIV-1-uninfected individuals.
    Musey L; Ding Y; Elizaga M; Ha R; Celum C; McElrath MJ
    J Immunol; 2003 Jul; 171(2):1094-101. PubMed ID: 12847284
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [HIV/AIDS vaccines: heading for new vaccine approaches?].
    Girard MP
    Bull Soc Pathol Exot; 2008 Jun; 101(3):220-6. PubMed ID: 18681215
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience.
    Ferrantelli F; Buttò S; Cafaro A; Wahren B; Ensoli B
    Springer Semin Immunopathol; 2006 Nov; 28(3):289-301. PubMed ID: 16983452
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Challenges in the development of an HIV-1 vaccine.
    Barouch DH
    Nature; 2008 Oct; 455(7213):613-9. PubMed ID: 18833271
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HIV-1 DNA vaccines.
    Fomsgaard A
    Immunol Lett; 1999 Jan; 65(1-2):127-31. PubMed ID: 10065638
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.
    Hone DM; DeVico AL; Fouts TR; Onyabe DY; Agwale SM; Wambebe CO; Blattner WA; Gallo RC; Lewis GK
    J Hum Virol; 2002; 5(1):17-23. PubMed ID: 12352264
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advances and challenges in recombinant Mycobacterium bovis BCG-based HIV vaccine development: lessons learned.
    Kilpeläinen A; Maya-Hoyos M; Saubí N; Soto CY; Joseph Munne J
    Expert Rev Vaccines; 2018 Nov; 17(11):1005-1020. PubMed ID: 30300040
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of prophylactic AIDS vaccines: the current state of affairs.
    Hanke T
    Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.